AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $515.60 ($509.48–$518.65, $4.90M total) across 10 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Aug 19, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, offering a modest trading signal.

02

Market read

Insider sale of $4.9M by the CEO may prompt short‑term price adjustment; relevance primarily to UTHR shareholders.

03

What to watch

Potential tax planning or diversification needs of the CEO; no negative operational news accompanies the sale.

Relevance 5/10Novelty 6/10Timing: post‑market 2026‑08‑18

Background

Form 4 filing reveals insider transactions; such disclosures are primary sources for market participants.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $4.9M of United Therapeutics shares via a 10b5‑1 plan on 2026‑08‑18.

Expected impact

Modest downside pressure; price could dip 1‑2% in the next trading session.

Evidence & confidence

CEO insider sales are closely watched; the $4.9M amount is material for a mid‑cap biotech, but no accompanying corporate event suggests a limited impact.

Market effects

Sector

May raise caution for biotech sector investors monitoring insider activity.

Regional

Limited to U.S. markets; no broader regional effect.

Global

Minimal global relevance beyond United Therapeutics shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals; price may remain stable.

Key entities

  • company
    United Therapeutics Corp

    NASDAQ‑listed biotech firm focused on organ transplantation and cell therapy.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min